News
Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...
Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...
Zacks Investment Research on MSN8h
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...
Soy Nómada on MSN9h
Medicare and Medicaid Could Start Covering Anti-Obesity DrugsA groundbreaking initiative from the Trump administration could revolutionize access to costly weight-loss drugs under Medicare and Medicaid. This plan aims to provide millions of Americans suffering ...
Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.
Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...
Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback